Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620576 · ClinicalTrials.gov registry record · Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
A Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT05620576 is a Phase 2 study of Diabetic Peripheral Neuropathic Pain that has completed, run by Eli Lilly and Company. The registered enrollment target is 131 participants, below the 419-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05620576, a Phase 2 study of Diabetic Peripheral Neuropathic Pain, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3857210
Study Locations (20)
Florida
- Accel Research Sites- Clinical Research Unit - DeLand
- Suncoast Research Group - Miami
- University of Miami Don Suffer Clinical Research Building - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
- Synexus Clinical Research US, Inc - Orlando - Orlando
- Synexus Clinical Research US, Inc. - Pinellas Park
Massachusetts
- Boston Clinical Trials - Boston
- ActivMed Practices and Research - Methuen
- MedVadis Research Corporation - Waltham
Arizona
- Synexus Clinical Research US, Inc. - Chandler
- Arizona Research Center - Phoenix
California
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Georgia
- North Georgia Clinical Research - Woodstock
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620576
The ClinicalTrials.gov registry entry for NCT05620576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 419-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (69% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05620576 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05620576 about?
NCT05620576 is a clinical study titled "A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).". This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chr...
What is the current status of trial NCT05620576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2022-11-14. Estimated completion is 2023-08-01.
What conditions does trial NCT05620576 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT05620576?
The interventions under investigation include: Placebo (DRUG), LY3857210 (DRUG).
Who is sponsoring clinical trial NCT05620576?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05620576 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.